Annual Congress- Hematologic Malignancies

Annual Congress: Hematologic Malignancies

Registration Now Open!
NCCN 2022 Annual Congress: Hematologic Malignancies™
Friday, October 14, 2022 – Saturday, October 15, 2022
New York, New York
Virtual attendance option available

The NCCN 2022 Annual Congress: Hematologic Malignancies^TM is a 1.5-day, CE-certified event focused on the latest advances in hematologic malignancies. Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, this program features panel discussions with world-renowned experts, interactive presentations, and challenging patient cases that highlight recent updates to the NCCN Guidelines^®, new and emerging therapeutic agents, and practical management strategies for patients with hematologic malignancies.

Register now for access to high-quality educational content, networking opportunities, and more. Attendees have the option to attend either in-person in New York or remotely through a virtual event platform.

Join us in New York again! Those attending in-person will have additional networking opportunities, including a Welcome Reception on Friday evening. Those attending onsite will also receive complimentary breakfast, lunch, and refreshments during breaks.

Attention In-Person Attendees! Proof of COVID-19 vaccination will be required for on-site attendance. Please click here for additional details. Instructions on how to submit proof of vaccination will be sent to all in-person registrants closer to the date of the meeting.

In-person and virtual attendees will have full access to all on-demand sessions, the ability to attend all live sessions, an opportunity to engage in interactive question-and-answer sessions with speakers, and access to the NCCN Exhibition Hall.

Continuing Education

This year’s agenda includes 18 on-demand and live educational sessions designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies. The program is approved for AMA PRA Category 1 Credit™ and ABIM MOC points for physicians and also is certified for credit for nurses, pharmacists, and other oncology professionals.

Agenda topics include:

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
CLL/SLL
Chronic Myeloid Leukemia
Diffuse Large B-cell Lymphoma
Hematopoietic Growth Factors
Hodgkin Lymphoma

Mantle Cell Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Myeloproliferative Neoplasms
Systemic Amyloidosis
Systemic Mastocytosis
Vaccines

For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.

Exhibition Hall

Visit the NCCN Exhibition Hall in-person and virtually for networking opportunities and to gather the latest information from industry-sponsored exhibits, the Patient Advocacy Pavilion, and more.

View Exhibitor Prospectus

For exhibitor opportunities, contact Jennifer Tredwell, Vice President, Marketing and Communications

Related Program

NCCN 2022 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™
Saturday, October 15, 2022
New York, New York
Registration is separate from the NCCN Hematologic Malignancies Congress. Virtual attendance option available.

2021 Recorded Sessions

View Recorded Presentations

Topics Include:

Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia
Debate – Response Milestones that Matter in Chronic Myeloid Leukemia: MMR vs. CCyR
Patient Case Studies and Panel Discussion: Leukemias
Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
Recommendations for Managing Adults with Histiocytic Neoplasms: New NCCN Guidelines
Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?
Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
Patient Case Studies and Panel Discussion: Lymphomas
Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease
Optimizing First-Line Therapy for Advanced Stage Classic Hodgkin Lymphoma

View Recorded Presentations

Accreditation

This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.

Related Programs

Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ are now available.

View Recorded Presentations

2021 Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo; Gilead Sciences, Inc. and Kite, A Gilead Company; GlaxoSmithKline; Novartis; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; Seagen Inc. (formerly Seattle Genetics, Inc.); and Takeda. This educational activity is supported by a medical education grant from Karyopharm® Therapeutics. This activity is supported by independent medical education grants from ADC Therapeutics, Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals. This activity is supported by an independent educational grant from Merck & Co., Inc. This activity is supported by an independent medical education grant from Bristol Myers Squibb. Provided by an independent medical education grant from MorphoSys.

2021 Commercial Sponsors

Save the dates!

NCCN 2023 Annual Congress: Hematologic Malignancies™
Hilton San Francisco Union Square • San Francisco, California
Friday, September 22, 2023 – Saturday, September 23, 2023